Search the GHTC website

Global health R&D delivers for Vermont

US government investment in global health R&D has delivered

$22.3 million
to Vermont research institutions
250+ new jobs
for Vermont
Vermont's top USG-funded global health R&D institutions

Vermont's top USG-funded global health R&D institutions

University of Vermont and State Agricultural College
$21.1 million
Quantaspec Inc.
$1.2 million

Vermont's top areas of global health R&D by USG funding

Diarrheal diseases
Neglected tropical diseases
Kinetoplastid diseases
Multi-disease/health area R&D
Global health R&D at work in Vermont

Researchers at the University of Vermont (UVM) College of Medicine are working to develop a broad-spectrum antiviral drug that could be used to combat several different families of RNA viruses, including coronaviruses like COVID-19, arenaviruses like Lassa fever, and filoviruses like Ebola and Marburg. The UVM team discovered a human protein that is irrelevant to human health but plays a key role in how RNA viruses take hold in the body. By screening existing drug compounds with artificial intelligence technology, researchers hope to identify compounds that target the specific protein, which would then serve as the basis for further drug development. Broad-spectrum antivirals are urgently needed. While treatments exist for COVID-19 and Ebola Zaire, we still lack therapies for most of the other diseases caused by RNA viruses.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: US Department of Energy